1. Introduction {#s0005}
===============

In recent years, stereotactic body radiotherapy (SBRT) has developed into standard clinical care for patients with oligometastases in many centers [@b0005], [@b0010], [@b0015]. Based on the oligometastatic disease paradigm [@b0020], treatment of individual metastatic lesions is being used to treat patients with limited metastatic disease to postpone the start of systemic therapies and ideally improve the progression-free survival or overall survival without compromising the quality of life [@b0005], [@b0025], [@b0030], [@b0035].

Experience with minimally invasive therapies such as stereotactic body radiotherapy (SBRT) as alternative to surgery has mainly been gained for inoperable patients with liver and lung oligometastases [@b0040], [@b0045], [@b0050], [@b0055], [@b0060], [@b0065]. However, SBRT has since been incorporated in standard clinical care for lymph node and bone oligometastases [@b0030], [@b0070], [@b0075] and is also being used for oligometastases located in adrenal glands [@b0080], [@b0085]. The minimally invasive nature of SBRT can be an advantage compared with surgical resection [@b0005], [@b0040], especially for small target structures such as metastatic lymph nodes.

With prostate specific membrane antigen positron emission tomography (PSMA-PET) small metastatic nodes can be detected in a very early stage with less than 10 mm and even less than 5 mm short axis diameter [@b0090]. In the majority of patients treated with SBRT for oligometastatic lymph nodes, the affected nodes originate from prostate cancer and like the primary tumors, have a low alpha/beta ratio [@b0095]. This is considered one of the reasons for responding very well to SBRT, with local control being achieved in 98.1% of patients in a pooled analysis [@b0100]. For oligometastases from other origins, a biological effective dose \>100 Gy is also thought to be beneficial for achieving local control [@b0005], but this will require a higher dose per fraction. In general, toxicity for SBRT of lymph node oligometastases is reported being mild, with on average 3% acute grade 2, 1% late grade 2, 0.3% acute grade 3 and 0.4% late grade 3 toxicity [@b0010]. For prostate cancer oligometastases, SBRT can delay the start of androgen deprivation therapy (ADT) with approximately 8--13 months [@b0025], [@b0030], thereby hopefully maintaining the patient's quality of life and avoiding the side effects of ADT such as sexual dysfunction [@b0105].

SBRT for oligometastases has mainly been applied with cone beam computed tomography (CBCT) linear accelerators (linacs) or CyberKnife, with fractionation schedules ranging from 5 × 5--10 Gy to 1 × 12--24 Gy [@b0100]. Single fraction SBRT has been used in some centers, in several cases aided by fiducial marker implantation [@b0110], [@b0115], [@b0120], [@b0125], [@b0130]. To our knowledge, peer reviewed reports on the accuracy of lymph node targeting with CBCT are lacking. However, in our own clinical routine about 30% of metastatic lymph node (as detected by diagnostic PET-CT and MRI) are poorly visible on CBCT [@b0135]. Compared to CBCT, magnetic resonance imaging (MRI) provides superior visualization of soft tissue targets with metastatic lymph nodes being one example [@b0140].

The combination of online MRI for target and organ at risk (OAR) delineation, full online treatment planning and MRI for position verification is realized in the 1.5T MR-linac (combined 1.5T MR scanner and linear accelerator, Unity, Elekta AB, Stockholm, Sweden) [@b0145], [@b0150]. New treatment plans based on the actual anatomy as depicted on MRI can be generated for every treatment fraction and online position verification is based on MRI information. The anatomy can be visualized during radiotherapy delivery (beam-on MRI) and after radiation delivery. With these facilities on board seeing the metastatic nodes with MRI and zapping them with SBRT comes into reach, as does high dose single fraction SBRT without fiducial markers. Furthermore, the daily anatomy of nearby OAR can easily be taken into account for daily treatment planning [@b0150], which may decrease treatment related toxicity and increase the number of patients eligible for single fraction treatments [@b0135], [@b0155], [@b0160].

However, despite the expected gain there are still uncertainties with regard to 1.5T MR-linac treatments in general and for lymph node metastases SBRT in particular. The clinically used PTV margin is still based on experiences at CBCT-linac, intra-fraction analyses using diagnostic MRIs and MR-linac commissioning data. In addition, the quality of inter-fraction correction with the 1.5T MR-linac with the two distinct online planning workflows: 'adapt to position' (ATP) and 'adapt to shape' (ATS) has not been investigated based on clinical data. The dosimetric effects of these different planning strategies may significantly affect the treatment benefit of online MRI guidance.

The objective of this manuscript is to demonstrate how close we are to "See it and Zap it" when treating lymph node oligometastases in the pelvis and para-aortic region with SBRT on the 1.5T MR-linac. Focus will be on 1) the suitability of ATS and ATP for correcting for inter-fraction motion and 2) the feasibility of delivering the dose adequately with ATS and ATP with a pre-defined PTV margin of 3 mm.

2. Material and methods {#s0010}
=======================

2.1. Patient characteristics {#s0015}
----------------------------

Ten patients were treated for single pelvic lymph node oligometastases on the 1.5T MR-linac (Unity, Elekta AB, Stockholm, Sweden) at our institute between August 2018 and February 2019. The metastatic lymph nodes were located in the pelvic region for seven patients, the other three patients had para-aortic lymph nodes (at the levels of L2-Th12 vertebral bodies). The patients with para-aortic lymph nodes received a 4D CT to assess whether the breathing induced target motion amplitude was within limits. For eight patients, the metastatic nodes originated from prostate cancer and were detected using Gallium-68 PSMA PET scans. The primary tumor was rectal or esophageal cancer for two patients, diagnosis of these lymph nodes was based on 2-deoxy-2-fluorine-18-fluoro-D-glucose PET ((18)FDG-PET). The metastatic lymph nodes were diagnosed within median 49 months \[range 18--159\] after initial diagnosis of the primary tumor. All patients have provided written informed consent for using their data as part of an ethics review board approved observational study. The median short-axis diameter of the metastatic lymph nodes was 7.5 mm \[5.3--21.3 mm\].

2.2. Clinical treatment {#s0020}
-----------------------

Pre-treatment preparation consisted of MR imaging followed by CT-based treatment planning using the anatomical information of the registered MRI. For pre-treatment CT scan acquisition a special table overlay was used to enable patient set-up using specific couch index points. By doing so the position of the patient along the length of the couch is known and reproducible between the CT scan and each MRI based treatment session [@b0150]. To reduce eventual motion, patients with lymph node metastases in the pelvic region were immobilized using a vacuum mattress (BlueBAG, Elekta AB, Stockholm, Sweden) with both hands on the chest and the elbows along the body. The patients with affected nodes in the para-aortic region were treated whilst wearing an abdominal corset [@b0165] with the arms along the body.

Nodal targets were treated with a GTV-PTV margin of 3 mm. For each patient, a seven-beam IMRT pre-treatment plan [@b0170] was created using Monaco TPS (Elekta AB, Stockholm, Sweden), taking into account the presence of the 1.5T magnetic field. For patients treated with the arms along the body, beam angles were selected such that the beams would not traverse the arms. OAR dose was lowered as much as possible, while maintaining a sufficient PTV coverage of V~35Gy~ \> 95% and a D~max~ between 120 and 135%. Clinical dose criteria for the OARs were based on the UK SABR consortium guidelines (2016) ([Table 1](#t0005){ref-type="table"}).Table 1Clinical dose criteria.StructureOffline constraints (pre-treatment plan)Online constraintsPlanning target volumeV~35Gy~ \> 95%\
D~0.1\ cm3~ \< 47.25 GyV~35\ Gy~ \> 95%\
D~0.1\ cm3~ \< 47.25 GyAortaV~53Gy~ \< 0.5 cm^3^V~53Gy~ \< 0.5 cm^3^BladderV~38Gy~ \< 0.5 cm^3^\
V~18.3Gy~ \< 15 cm^3^V~38Gy~ \< 0.5 cm^3^Bowel bag + ColonV~32Gy~ \< 0.5 cm^3^\
V~25Gy~ \< 10 cm^3^V~32Gy~ \< 0.5 cm^3^Duodenum + StomachV~35Gy~ \< 0.5 cm^3^\
V~25Gy~ \< 10 cm^3^V~35Gy~ \< 0.5 cm^3^EsophagusV~34Gy~ \< 0.5 cm^3^\
V~27.5Gy~ \< 5 cm^3^V~34Gy~ \< 0.5 cm^3^KidneyV~16.8Gy~ \< 67%V~16.8Gy~ \< 67%Nerve root + sacral plexusV~32Gy~ \< 0.1 cm^3^V~32Gy~ \< 0.1 cm^3^Rectum + SigmoidD~max~ \< 40 Gy\
V~32Gy~ \< 0.5 cm^3^V~32Gy~ \< 0.5 cm^3^Spinal cordD~max~ \< 28 GyD~max~ \< 28 GyUreterD~max~ \< 40 GyD~max~ \< 40 Gy

With online MR imaging as provided in the 1.5T MRI-linac, the pre-treatment plan can be adapted by either 1) taking the new target position into account (adapt to position, ATP) and optimizing on the pre-treatment CT and contours after a rigid registration and translation or 2) using the new patient anatomy (adapt to shape, ATS) and optimizing on the daily image and adapted contours ([Fig. 1](#f0005){ref-type="fig"}). For our clinical treatments plan adaptation was performed using the ATS workflow. During each treatment session, a daily MRI was acquired. Contours were automatically deformed. If necessary, the contours of the target lymph node(s) and OARs within 2 cm of the PTV(s) were manually adapted by a radiation oncologist [@b0150]. Based on the daily MRI and the adapted contours, a completely new treatment plan was generated using segment shape and weight optimization based on a newly optimized fluence [@b0175]. Radiation delivery according to the new plan was performed after MRI based position verification.Fig. 1Schematic overview of the differences between the MR-linac Unity "adapt to shape" method in which online plan adaptation is performed on the new patient anatomy and optimized on the daily MRI and adapted contours, and the "adapt to position" method in which online plan adaptation is performed based on the new patient position and optimized on the pre-treatment CT and contours. Using the "adapt to position" method, rigid registration can be performed on the entire image sets, or using a clipbox around a region of interest [@b0180].

After each treatment session offline assessment of the intra-fraction motion was performed by recalculating the GTV coverage on the actual anatomy as seen on the post-delivery MRI, which was acquired on average 31:03 ± 3:40 min after the online planning MRI. Contouring of the GTV on the post-delivery MRI was performed by a single observer. Inter-observer contouring variation is considered negligible for these small and well visible lesions.

2.3. Retrospective analyses {#s0025}
---------------------------

### 2.3.1. ATS versus ATP based plan adaptation {#s0030}

To investigate the suitability for correcting for inter-fraction motion the dosimetric impact of plan adaptation based on the new patient position (ATP) versus plan adaptation using the daily anatomic information and contours (ATS) was evaluated. An additional plan was retrospectively created for each treatment fraction using the ATP workflow with segment shape and weight optimization. Because the resulting dose-volume histogram parameters for an ATP plan are based on the pre-treatment CT contours and may essentially give a false representation of the actual situation, these plans have additionally been calculated on the daily MRI and contours. The GTV and PTV coverage was then compared for each of these 3 plans; the clinically delivered ATS plans, the ATP plans and the ATP plans calculated on the daily anatomy.

### 2.3.2. GTV target coverage analysis {#s0035}

To determine whether dose coverage was sufficient during treatment and if PTV margins were adequate, the GTV coverage for the clinically delivered (ATS) plans and the ATP plans was evaluated. This was done by evaluating the dose on both the online planning MRI, acquired at the start of the treatment fraction, as well as the post-delivery MRI, acquired after dose delivery.

### 2.3.3. PTV margin determination {#s0040}

The PTV margin was re-evaluated using data of these first 10 patients with single lymph node metastases treated on the MR-linac. The margin M~PTV~ required to ensure a minimum dose to the GTV of 35 Gy for 90% of the patients was calculated using the Van Herk recipe [@b0185] given by$$M_{\mathit{PTV}} = \alpha\Sigma + \beta\sigma - \beta\sigma_{p}$$with α = 2.5, β = 0.84 and σ~p~ = 3.2 mm. A β value of 0.84 was used assuming a stereotactic treatment with a plateau-prescription dose ratio of 1.25 and maximum short axis diameter of the GTV \> σ. σp defines the standard deviation that describes the width of an idealized Gaussian penumbra for the total dose distribution in water, which was approximately valid because electron densities were assessed to electron density of water except for the bones [@b0150]. $\sigma = \sqrt{\sigma_{\mathit{intra}}^{2} + \sigma_{p}^{2}}$ defines the total random error and $\Sigma = \sqrt{\Sigma_{\mathit{intra}}^{2} + \Sigma_{\mathit{MV} - MRI}^{2} + \Sigma_{\mathit{MRI}}^{2}}$the total systematic error. This recipe is still adequate for hypo-fractionated treatments when σ~intra~\<\<σ~p~ [@b0190] and the effective systematic and random errors are used [@b0195]. Delineations errors were not taken into account assuming that the physician includes the GTV generously as had been decided by forehand. The different error sources were also assumed to be statistically independent and normally distributed.

Both Σ~MV-MRI~ and Σ~MRI~ were based on 3D vector measurements in our clinic. The contributions to the systematic errors were assumed isotrope. $\Sigma_{\mathit{MV} - MRI} = 0.3/\sqrt{3}\mspace{6mu} mm$ was obtained from Raaymakers et al. [@b0145] which defines the global error between the machine and MRI coordinate system. $\Sigma_{\mathit{MRI}} = 0.84/\sqrt{3}\mspace{6mu} mm$ was determined during commissioning and describes the maximum residual geometric errors after gradient non-linearity correction within a 200 mm diameter spherical volume (DSV). This was measured on a large geometric fidelity phantom as described in Tijssen et al [@b0200]. To obtain the systematic (Σ~intra~) and random (σ~intra~) group error due to intra-fraction motion, the distance in center of gravity of both GTV delineations, on the online MRI and post treatment MRI, was calculated for all five fractions of each patient. The intra-fraction deviations were then defined as the distance in center of gravity divided by two. The methodology given in Stroom and Heijmen. [@b0205] was used to determine the group mean M (mean-of-means), systematic group error (defined as the standard deviation of the means) and random group error (defined as the root-mean-square of the standard deviations). The effective systematic error and effective random error were equal to the derived systematic and random error because the errors due to intra-fraction motion were already based on only 5 fractions. In case the group mean M significantly differed from zero, M was added to margin M~PTV~.

3. Results {#s0045}
==========

3.1. ATS versus ATP plan adaptation {#s0050}
-----------------------------------

The clinically delivered ATS plans show the highest PTV coverage with a median V~35Gy~ of 99.9% \[90.7--100%\] and GTV coverage with a median V~35Gy~ of 100% \[99.7--100%\]. For 9 fractions, PTV coverage was reduced during online planning to meet OAR constraints. The ATP plans, evaluated on the pre-treatment CT, also show sufficient target coverage with a median PTV V~35Gy~ of 98.5% \[91.0--99.9%\] and GTV V~35Gy~ of 100% for all fractions. However, after calculating the ATP plans on the new MRI based anatomy and contours, the PTV coverage is significantly lower (*p*-value \< 0.01, Wilcoxon matched-pairs signed rank test) with a median PTV V~35Gy~ of 93.6% \[76.3--99.7%\] and a median GTV V~35Gy~ of 100% \[93.9--100%\]. Additionally, a larger variance between target coverage is observed ([Fig. 2](#f0010){ref-type="fig"}). If an OAR dose constraint violation occurred, the violation was with a maximum of 2 Gy or 0.2 cc for both methods.Fig. 2Boxplot of the target dose coverage (N = 50 fractions) described as planning target volume (PTV) and gross target volume (GTV) V~35Gy~ in % for the adapted treatment plans. The bars show the upper and lower quartiles. The whiskers show the minimum and maximum values, excluding outliers (1.5 times the interquartile range) which are denoted with an asterisk. The target coverage for the adapt to shape plans is evaluated on the daily MRI. The target coverage for the adapt to position (CT) plans is evaluated on the pre-treatment CT and the target coverage for the adapt to shape (MRI) plans is evaluated on the daily MRI.

3.2. GTV target coverage analysis {#s0055}
---------------------------------

For the clinically delivered ATS plans the median GTV V~35Gy~ was 100% \[99.7--100%\] and the median GTV D~mean~ was 42.3 Gy \[37.6--44.7 Gy\] on the online planning MRI. On the post-radiation delivery MRI the median GTV V~35Gy~ was 100% \[98.0--100%\] and the median GTV D~mean~ was 42.2 Gy \[37.9--44.7 Gy\] ([Fig. 3](#f0015){ref-type="fig"}). For 45 of the 50 fractions (90%) the GTV V~35Gy~ on the post-delivery MRI remained 100%. For one patient, a slight reduction of the GTV coverage was necessary during online treatment planning for 3 fractions due to the dose constraint for the sacral plexus in the vicinity of the target. For the ATP plans the median GTV V~35Gy~ was 100% \[93.9--100%\] and the median GTV D~mean~ was 41.6 Gy \[39.0--43.6 Gy\] on the online planning MRI. On the post-radiation delivery MRI the median GTV V~35Gy~ was 100% \[93.4--100%\] and the median GTV D~mean~ was 41.5 Gy \[38.9--43.7 Gy\]. For 35 of the 50 fractions (70%) the GTV V~35Gy~ was 100% on the post-delivery MRI. [Fig. 4](#f0020){ref-type="fig"} shows a visual example.Fig. 3Boxplot graph of the GTV coverage (N = 50) described as V~35Gy~ in % and D~mean~ in Gy for the clinically delivered (ATS) plans and the ATP plans. The bars show the upper and lower quartiles. The whiskers show the minimum and maximum values, excluding outliers (1.5 times the interquartile range) which are denoted with an asterisk. The coverage is evaluated on the daily MRI.Fig. 4Sample case with intra-fraction expansion of the bladder due to increased filling. Visible are the 35 Gy dose level (red), the PTV (blue) and the actual location of the GTV (green) for the ATP plan on the online planning MRI (A) and the post-delivery MRI (B) and the ATS plan on the online planning MRI (C) and the post-delivery MRI (D). The GTV V~35Gy~ remained 100% for the clinically delivered (ATS) plan. For this particular case the increasing bladder filling and GTV shift resulted in a small reduction of GTV V~35Gy~ from 100% to 97.5% with the ATP plan. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

3.3. PTV margin analyses {#s0060}
------------------------

The systematic and random intra-fraction displacement errors were respectively 0.31 and 0.27 mm in AP-direction, 0.54 and 0.23 mm in CC-direction and 0.22 and 0.33 mm in LR-direction. Only in AP-direction the group mean M (mean-of-mean) was significantly different from zero. The targets moved systematic in posterior direction during the individual MR-linac treatments. The group mean M was 0.33 mm in AP-direction, −0.07 mm in CC direction and 0.04 mm in LR-direction. The required PTV margin was estimated being 1.5 mm in LR-direction, 1.8 in AP-direction and 1.9 in CC-direction, respectively. [Fig. 5](#f0025){ref-type="fig"} shows two examples of intra-fraction motion.Fig. 5Example cases intra-fraction target motion of lymph node oligometastases in the pelvic (A) and para-aortic (B) region. Visible are the post-delivery MRIs with the online planning GTV (green) and the GTV as observed on the post-delivery MRI (red). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

4. Discussion {#s0065}
=============

MRI guided radiotherapy has been established during the last two decades. Broad clinical implementation has been realized for brachytherapy indications, mainly cervix and prostate [@b0210], [@b0215], [@b0220]. Clinical gain of MRI guided brachytherapy in terms of local control and survival, not to the cost of treatment related morbidity, has been demonstrated for all stages of advanced cervical [@b0225], [@b0230] and for prostate cancer [@b0235]. In parallel, MRI guidance has become clinically available for external beam radiotherapy (EBRT) in 2014 with the combination of a 0.3 T MRI and 60 Cobalt radiotherapy device as realized in MRidian [@b0240]. Since 2017 the combination of a 1.5T MRI and 7MV linear accelerator is available, bringing new opportunities for MRI guided high accuracy radiotherapy [@b0145]. Since July 2018 this radiotherapy system is increasingly available for clinical routine treatments, starting in Europe and North-America with potential for global spread.

In our institute first clinical treatments on the 1.5T MR-linac were performed for patients with single oligometastatic lymph nodes in pelvis and para-aortic region. All nodes were well visible on the MRIs taken for treatment planning and position verification. The nodes were treated with SBRT (5 × 7 Gy) and the ATS online planning option, which allows to correct for inter-fraction motion by full online treatment planning based on the actual anatomy. All treatment planning aims were met for 40 out of 50 fractions. For 10 fractions the PTV coverage had to be sacrificed slightly in order to meet the hard constraints for OAR adjacent to the nodes and in 3 of these fractions the GTV coverage of the online plan was slightly less than intended (minimum 99.7%). In case the ATP workflow had been used online optimization would have been performed on the pre-treatment patient anatomy. In this case our treatment planning aims would have been met for only 19 out of 50 fractions and the GTV V~35Gy~ was reduced to 93.9% in the worst case. These clinical results show the additional dosimetric benefit of adaptive MRI-guided radiotherapy with online treatment planning based on the actual patient anatomy. In case of (hypo)-fractionated treatment approaches eventual inter-fraction anatomical changes can be accounted for. Because the ATS workflow is relatively labour-intensive compared to ATP, future studies will aim at predicting for which patients ATS would be most beneficial, and for whom ATP would also provide sufficient target coverage.

When evaluating the dose distributions of the online treatment plan on the anatomy of the post-treatment anatomy the chosen isotropic PTV margin of 3 mm turned out being adequate for treating single lymph nodes in the pelvis and para-aortic region on the MR-linac with the ATS treatment planning option. A limitation of this method is that potential system errors (e.g. MV-MR misalignments) are not accounted for. The PTV margin has to account for system errors as well as intra-fraction target motions and was therefore re-evaluated. Based on the Van Herk recipe [@b0185] an isotropic PTV margin of 2 mm would have been adequate in all three directions in our series. However, noting the limitations of the recipe for SBRT treatments, very small tumors and higher density structures [@b0190], [@b0245] we will still use a PTV margin of 3 mm for this particular indication in further treatments.

Within the group of oligometastatic nodal disease gain in terms of PTV margin reduction and less dose to the surrounding is especially expected for multiple metastatic lesions. In this situation daily treatment planning according to the daily anatomy might attenuate the effect of relative position shifts of the individual nodes relative to each other due to the changes of surrounding organs. Position shifts of pelvic lymph nodes are caused by movements and volume changes of the surrounding organs [@b0250] and are not comparable to the intra-fraction motions of thoracic and abdominal lymph nodes, which are mainly affected by breathing [@b0255], [@b0260]. Dosimetric gain of 1.5T MR-linac treatments is also expected in other tumor sites with potentially large inter and intra-fraction motion and substantial deformations such as prostate [@b0265], cervix [@b0270], and rectum [@b0275].

A factor with potential impact on the PTV-margin is the time needed for an entire MR-linac treatment procedure. On-couch time for single lymph node SBRT is currently between 30 and 45 min in our clinical routine. The majority of this time is occupied by treatment planning and radiation delivery with IMRT, which is considerably longer than the few minutes being needed to deliver a VMAT plan as available for CBCT machines. However, when comparing the CBCT-linac single plan option for all treatment fractions with the daily treatment plan option of the 1.5T MR-linac we see dosimetric gain for target and/or OARs [@b0180]. Further PTV margin reduction and dosimetric gain of MR-linac treatments is to be expected with intended machine and software updates. Less time consuming MRI protocols and treatment planning algorithms, VMAT instead of IMRT, tumor tracking during irradiation are among the options currently being developed.

Gain for our patients will include improved comfort through further hypo-fractionation with single fraction treatments on the MR-linac being aimed at as final goal. Due to the excellent soft tissue contrast of MRI treatment margins can be small, fiducial marker implantation as applied by others for position verification purposes can be avoided [@b0110], [@b0115]. Clinical gain in terms of tumor related outcome such as local control, prolonged survival, later onset of systemic treatment as well as morbidity and quality of life is yet to be established.

Our study is limited by the relatively low number of cases available for the retrospective evaluation of ATS and ATP planning approaches and the margin analysis. The nodes, which are mainly originating from prostate cancer were detected by PSMA-PET, reflect small volume targets and essential volume reductions during the course of treatment are not expected [@b0280]. Regardless of these limitations, the here presented findings correspond to earlier reported pre-clinical investigations [@b0135], [@b0175] and validate our current treatment approach.

In conclusion, metastatic lymph nodes in the pelvis and para-aortic region can be treated on the 1.5T MR-linac within an acceptable time frame for the whole treatment procedure. We can effectively perform MRI based online treatment planning taking into account the actual patient anatomy and deliver the intended dose to the targets using small but adequate treatment margins. We feel that we are close to "See it and Zap it" with single fraction treatments including MRI based tumor tracking as final goal.
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